Connor Clark & Lunn Investment Management Ltd. Has $422,000 Stock Holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO)

Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 11.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 200,032 shares of the medical instruments supplier’s stock after buying an additional 20,026 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.46% of Harvard Bioscience worth $422,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Harvey Partners LLC boosted its position in shares of Harvard Bioscience by 6.2% in the third quarter. Harvey Partners LLC now owns 2,715,000 shares of the medical instruments supplier’s stock worth $7,303,000 after buying an additional 157,500 shares during the period. AMH Equity Ltd boosted its position in Harvard Bioscience by 4.7% during the fourth quarter. AMH Equity Ltd now owns 2,500,000 shares of the medical instruments supplier’s stock valued at $5,275,000 after purchasing an additional 111,132 shares during the last quarter. Geode Capital Management LLC boosted its position in Harvard Bioscience by 2.2% during the third quarter. Geode Capital Management LLC now owns 912,599 shares of the medical instruments supplier’s stock valued at $2,455,000 after purchasing an additional 19,972 shares during the last quarter. State Street Corp lifted its position in shares of Harvard Bioscience by 1.1% in the third quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock worth $1,930,000 after buying an additional 7,763 shares during the last quarter. Finally, Williams & Novak LLC acquired a new stake in shares of Harvard Bioscience in the fourth quarter worth about $209,000. Institutional investors and hedge funds own 80.87% of the company’s stock.

Harvard Bioscience Trading Down 3.3 %

Harvard Bioscience stock opened at $0.64 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.91 and a current ratio of 2.06. The business’s 50-day simple moving average is $1.28 and its 200-day simple moving average is $1.99. The firm has a market capitalization of $28.04 million, a PE ratio of -1.93 and a beta of 1.46. Harvard Bioscience, Inc. has a 52 week low of $0.60 and a 52 week high of $4.70.

Harvard Bioscience Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.